PROXY CORNER: Eli Lilly and Co.

Eli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 ( discovers, develops, manufactures and sells pharmaceutical products for humans and animals. For the quarter ended Dec. 31, 2009, the company reported net income of $915.4 million, or 83 cents per diluted share, on $5.9 billion in revenue. That compares with a net loss of $3.6 billion, or $3.31 per diluted share, on $5.2 billion in revenue in the same period a year ago. The company’s shares trade on the New York Stock Exchange under the ticker symbol LLY. Information for Proxy Corner was taken from Bloomberg News and from the company’s proxy statement dated March 8, 2010.

View full Proxy Corner feature

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}